Eyenovia & SGN Nanopharma Collaborate To Work To Develop SGN's Micellar Nanoparticle Platform Platform-Based Cyclosporine Formulation For Use With Eyenovia's Optejet Dispenser
Portfolio Pulse from Benzinga Newsdesk
Eyenovia, Inc. (NASDAQ:EYEN) and SGN Nanopharma have entered into a collaboration to develop a cyclosporine formulation for chronic dry eye disease using SGN's Micellar Nanoparticle Platform and Eyenovia's Optejet dispenser. The companies are validating the product's manufacturability and plan to consult with the FDA for clinical development.
July 30, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eyenovia, Inc. has entered into a collaboration with SGN Nanopharma to develop a new treatment for chronic dry eye disease. The companies are working on the manufacturability of the product and plan to consult with the FDA for clinical development.
The collaboration with SGN Nanopharma to develop a new treatment for chronic dry eye disease could potentially expand Eyenovia's product portfolio and market reach. The planned FDA consultation indicates progress towards clinical development, which is a positive signal for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100